Sumary of FDA staff declines to take stance on Pfizer’s Covid vaccine booster shots, citing lack of verified data:
- “Overall, data indicate that currently US-licensed or authorized COVID-19 vaccines still afford protection against severe COVID-19 disease and death in the United States,” they wrote.
- Science In separate documents released Wednesday, Pfizer argued a third dose of the Covid vaccine six months after a second shot restores protection from infection to 95%.
- “The staff report is meant to brief the FDA’s Vaccines and Related Biological Products Advisory Committee, which meets Friday to review Pfizer’s request to approve Covid booster doses for the general public.
- The Biden administration has said it wants to begin offering booster shots to the general public as early as next week, pending authorization from the FDA.
- The move is part of President Joe Biden’s broader plan to confront a higher number of Covid cases fueled by the fast-spreading delta variant.
- Scientists and other health experts have repeatedly criticized the plan, saying data the federal health officials cited wasn’t compelling and characterizing the administration’s push for boosters as premature.
- There is currently not a consensus in the biomedical community on boosters for the general public, said Dan Barouch, an immunologist at Harvard Medical School.
- “Right now, it’ll be interesting to see where the debate goes, but obviously it is known that the Biden administration has suggested that boosters are needed.